MedPath

Propofol Versus Midazolam for Lower Gastrointestinal Endoscopy

Phase 3
Conditions
Cirrhosis, Liver
Interventions
Registration Number
NCT03388151
Lead Sponsor
Sherief Abd-Elsalam
Brief Summary

propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy

Detailed Description

Effect of use of propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy, Randomised controlled trial.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Liver cirrhosis
  • presented to colonoscopy
Exclusion Criteria
  • Encephalopathy
  • Hypersensitivity
  • Coagulopathy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PropofolPropofolPropofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
MidazolamMidazolamMidazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
Primary Outcome Measures
NameTimeMethod
Number of patients adequately sedated6 months

The number of patients adequately sedated

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sherief Abd-Elsalam

🇪🇬

Tanta, Egypt

Sherief Abd-Elsalam
🇪🇬Tanta, Egypt
Sherief Abd-elsalam, lecturer
Contact
00201000040794
Sherif_tropical@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.